SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare enters into manufacturing license, technology transfer agreement with Enzychem

24 Nov 2021 Evaluate

Cadila Healthcare has entered into a manufacturing license and technology transfer agreement for its Plasmid DNA based Covid-19 (ZyCoV-D) vaccine with Enzychem Lifesciences (Enzychem) of Republic of Korea. The company will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences. Both Cadila Healthcare and Enzychem believe that this partnership will lead to an estimated manufacturing of 80 million or more doses of the Plasmid DNA vaccine in 2022.

Under the agreement, Enzychem will manufacture and commercialise the vaccine within its territory under a Zydus trademark and Cadila Healthcare will receive the license fees and royalty payments for the same. ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by Cadila Healthcare against the Covid-19 virus. The vaccine is administered intradermally using the PharmaJet needle free applicator, which ensures painless intradermal vaccine delivery.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

1159.85 10.85 (0.94%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: